US-based drug maker Eli Lilly and Co said it has issued non-exclusive and royalty free licenses to Indian pharma companies Cipla, Lupin and Sun Pharma to produce Lilly’s Baricitinib drugs as an initiative to combat the ongoing deadly second wave in India.
ELI LILLY PHARMA:
The pharmaceutical firm is also in talks with other Indian companies to provide more such voluntary licenses to expand the availability of its drug in the country. Notably, CDSCO has also given permission to use Baricitinib in combination with Remdesivir to treat COVID-19 tested positive adults in hospitals requiring other supplemental supports.
The voluntary and non-exclusive licensing provided to Indian pharmaceutical companies to produce the drug expands the availability of treatment options locally and ensures high quality production of the drug in India.
Also Read: Indian COVID-19 double mutant strain labelled as a “variant of concern” by WHO
Luca Visini, Managing Director, Indian Subcontinent, Lilly India has pledged to use the portfolio of Eli Lilly’s breakthrough sciences to help and support India’s current healthcare crises.
To help India win this battle against the COVID-19, the company has responded by providing licenses to Indian pharma companies to produce their drugs non-exclusively. More and more such licenses will be soon provided to companies to help India alleviate from the burden of the COVID-19. And, the company will also look forward for other such possibilities to support the healthcare system in India, said Visini.
Maharashtra vaccinates over 10.96 lakh people against COVID-19 in a single day
Maharashtra: 80% of the samples received were tested positive for the delta variant
Pune – Lonavala local train to resume soon for vaccinated passengers.